Top Markets
#1 Seeker Seeker +131.55%
#2 MowCat MowCat +108.83%
#3 Helium Helium +94.89%
#4 AI XOVIA AI XOVIA +91.25%
#5 Pons Pons +48.34%
#6 UnifAI Network UnifAI Network +33.34%
#7 Zora Zora +25.69%
#8 Bounce Bounce +25.32%
#9 Zylo Ecosystem Zylo Ecosystem +21.51%
#10 pipedog pipedog +18.86%
Coin of the day
Seeker Seeker
Settings
Language
ENGLISH
Currency
USD
Theme
Sunmax Biotechnology Co., Ltd. Sunmax Biotechnology Co., Ltd.

Sunmax Biotechnology Co., Ltd.

4728
Rank in Stocks #11505
Established in Tainan City, Taiwan, in 2001, Sunmax Biotechnology Co., Ltd.... Established in Tainan City, Taiwan, in 2001, Sunmax Biotechnology Co., Ltd. functions as a biomedical enterprise. The company specializes in the development, manufacturing, and commercialization of collagen-based medical devices across Taiwan and mainland China. Its diverse product line encompasses Porcogen, a sterile, purified collagen solution valuable for medical device applications, tissue engineering, and research. Sunmax also supplies various dermal fillers, including the Sunmax collagen implant series (I-Plus, I) and FACIALGAIN collagen implants (with and without lidocaine), engineered for correcting facial aesthetic concerns such as wrinkles. For dental procedures, they provide specialized collagen-based solutions like Sunmax collagen dental bone grafts, membranes, and granules, used for augmenting or reconstructing the alveolar ridge, extraction sockets, and in periodontics. Additionally, the Sunmax collagen bone graft matrix serves as a bone void filler that naturally resorbs and facilitates new bone formation during recovery. The company's offerings extend to skincare products, such as Sunmax 12 jiao didi spray, Sunmax 11 collagen moisturizing cream, and a general collagen skincare line, all designed for post-dermal filler treatment aftercare.
Share Price
$12.72
Last synced: 2026-08-27
Market Cap
$692.75M
Change (1 day)
0.00%
Change (1 year)
-4.67%
Country
TW
Trade Sunmax Biotechnology Co., Ltd. (4728)

Category

Healthcare
P/E ratio for Sunmax Biotechnology Co., Ltd. (4728)
P/E ratio as of 2026 TTM: 0
According to Sunmax Biotechnology Co., Ltd. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Sunmax Biotechnology Co., Ltd. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.